Psoriasis is a chronic inflammatory skin disease affecting more than 60 million people worldwide, characterized by painful ...

A new review has found that obesity worsens psoriatic arthritis severity and treatment response, calling for more integrated ...

More than 50 million Americans live with autoimmune diseases like rheumatoid arthritis, lupus, and psoriatic arthritis — and ...

Takeda has announced new data from the two pivotal phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe ...

Pain, systemic inflammation and HLA-B27 are the “strongest” predictors for psoriatic arthritis among patients with psoriasis, ...

Preliminary findings of the PREDICT study suggest that the DUET Ultrasound Enthesitis Score may improve the confidence with ...

Biologic exposure for psoriasis is not associated with an increased rate of adverse pregnancy outcomes when compared with ...

UCB SA is rated a Buy due to its successful pivot to high-growth immunology and neurology platforms. Learn more about UCBJF ...

While no association was observed between use of biologics and incident PsA overall, specific biologic classes were ...

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, ...

Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to ...

Jul 16, 2026-- Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a nex ...